Rydapt
Active Ingredient(s): MidostaurinFDA Approved: * April 28, 2017
Pharm Company: * NOVARTIS PHARMS CORP
Category: Cancer
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Rydapt Overview
Midostaurin, sold under the brand name Rydapt, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[1] Contents 1 AML and MDS 2 Systemic ma...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Midostaurin
Recent Rydapt Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Midostaurin
- Capsule: 25mg
NDC Database Records for Rydapt: (1 result)
Sorted by National Drug Code- 0078-0698 Rydapt 25 mg Oral Capsule, Liquid Filled by Novartis Pharmaceuticals Corporation